Gland Pharma Wenjie Zhang as a resigns
Gland Pharma (BSE: GLAND) said Wenjie Zhang as a has resigned; and Xingli Wang as an has been appointed. The company is valued at about ₹47,416 crore.
What happened
Gland Pharma (BSE: GLAND) informed the stock exchanges on 1 October 2026 at 03:54 PM that Wenjie Zhang as a has resigned; and Xingli Wang as an has been appointed.
From the filing: "Wenjie Zhang as a Non-Executive & Non-Independent Director and Appointment of Mr."
Company snapshot
Gland Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹47,416 crore.
The stock last traded at ₹2,874.4, against a 52-week range of ₹1,573.6–₹3,042 (5.5% below the high).
Before this filing the shares had moved +2.4% over the month and +19.6% over three months. Average daily turnover over the last 20 sessions was about ₹176 crore.
Promoters held 51.77% at the end of Q1 FY27, down 0.06% points from the previous quarter. Foreign institutions owned 8.74% and domestic institutions 30.44%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,506 | 215.5 | 13.08 |
| Q2 FY26 | 1,487 | 183.7 | 11.15 |
| Q3 FY26 | 1,695 | 261.5 | 15.87 |
| Q4 FY26 | 1,743 | 366.7 | 22.26 |
| Q1 FY27 | 1,800 | 317 | 19.23 |
What history shows
This is not the company's first management change disclosure: BCEIE has 7 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 1.0% on average the next trading day and was up 0.4% on average after five days (4 filings with price data).
Across 97 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +1.8% over five days; 51% of them rose the next day.
Market-wide, 3,837 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 14 Aug 2026 | Management change | −1.9% | −5.0% |
| 20 Jul 2026 | Change in Director(s) of the company. | −0.8% | −1.3% |
| 15 Jun 2026 | Management change | −0.7% | +3.8% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Gland Pharma Share Price Today Near Yearly High
- Mankind, Dr Reddy, Gland Pharma, others lift Nifty Pharma up over 1% as US exempts certain drugs from 100% tariffs
- Gland Pharma shares fall over 2% amid block deal report
- Gland Pharma and CAMS among 5 smallcap stocks sold by mutual funds in August
- Gland Pharma NSE:GLAND Newspaper Member Notice Sept 2026
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.